Radiopharmaceutical therapy delivers promising meningioma survival rates
The Phase II clinical trial is the first completed prospective trial for refractory meningiomas with a tumour growth rate of 15 percent or more over six months.
List view / Grid view
The Phase II clinical trial is the first completed prospective trial for refractory meningiomas with a tumour growth rate of 15 percent or more over six months.
The study shows modifying the standard of care for late-stage neuroendocrine tumours (NETs) with Evans blue dye makes the treatment more effective and potentially less toxic.